TY - JOUR
T1 - Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms
AU - Martinotti, Giovanni
AU - Pettorruso, Mauro
AU - De Berardis, Domenico
AU - Varasano, Paola Annunziata
AU - Pressanti, Gabriella Lucidi
AU - De Remigis, Valeria
AU - Valchera, Alessandro
AU - Ricci, Valerio
AU - Di Nicola, Marco
AU - Janiri, Luigi
AU - Biggio, Giovanni
AU - Di Giannantonio, Massimo
PY - 2016
Y1 - 2016
N2 - Background: Agomelatine modulates brain-derived neurotrophic factor expression via its interaction with melatonergic and serotonergic receptors and has shown promising results in terms of brain-derived neurotrophic factor increase in animal models. Methods: Twenty-seven patients were started on agomelatine (25 mg/d). Venous blood was collected and brain-derived neurotrophic factor serum levels were measured at baseline and after 2 and 8 weeks along with a clinical assessment, including Hamilton Depression Rating Scale and Snaith-Hamilton Pleasure Scale. Results: Brain-derived neurotrophic factor serum concentration increased after agomelatine treatment. Responders showed a significant increase in brain-derived neurotrophic factor levels after 2 weeks of agomelatine treatment; no difference was observed in nonresponders. Linear regression analysis showed that more prominent brain-derived neurotrophic factor level variation was associated with lower baseline BDNF levels and greater anhedonic features at baseline. Conclusions: Patients affected by depressive disorders showed an increase of brain-derived neurotrophic factor serum concentration after a 2-week treatment with agomelatine. The increase of brain-derived neurotrophic factor levels was found to be greater in patients with lower brain-derived neurotrophic factor levels and marked anhedonia at baseline.
AB - Background: Agomelatine modulates brain-derived neurotrophic factor expression via its interaction with melatonergic and serotonergic receptors and has shown promising results in terms of brain-derived neurotrophic factor increase in animal models. Methods: Twenty-seven patients were started on agomelatine (25 mg/d). Venous blood was collected and brain-derived neurotrophic factor serum levels were measured at baseline and after 2 and 8 weeks along with a clinical assessment, including Hamilton Depression Rating Scale and Snaith-Hamilton Pleasure Scale. Results: Brain-derived neurotrophic factor serum concentration increased after agomelatine treatment. Responders showed a significant increase in brain-derived neurotrophic factor levels after 2 weeks of agomelatine treatment; no difference was observed in nonresponders. Linear regression analysis showed that more prominent brain-derived neurotrophic factor level variation was associated with lower baseline BDNF levels and greater anhedonic features at baseline. Conclusions: Patients affected by depressive disorders showed an increase of brain-derived neurotrophic factor serum concentration after a 2-week treatment with agomelatine. The increase of brain-derived neurotrophic factor levels was found to be greater in patients with lower brain-derived neurotrophic factor levels and marked anhedonia at baseline.
KW - Agomelatine
KW - BDNF
KW - Major depressive disorder
KW - Pharmacology
KW - Pharmacology (medical)
KW - Psychiatry and Mental Health
KW - Agomelatine
KW - BDNF
KW - Major depressive disorder
KW - Pharmacology
KW - Pharmacology (medical)
KW - Psychiatry and Mental Health
UR - http://hdl.handle.net/10807/94655
UR - http://ijnp.oxfordjournals.org/
U2 - 10.1093/ijnp/pyw003
DO - 10.1093/ijnp/pyw003
M3 - Article
SN - 1461-1457
VL - 19
SP - pyw003-N/A
JO - International Journal of Neuropsychopharmacology
JF - International Journal of Neuropsychopharmacology
ER -